1. Home
  2. CRNX vs BGSI Comparison

CRNX vs BGSI Comparison

Compare CRNX & BGSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.70

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

BGSI

Boyd Group Services Inc.

N/A

Current Price

$97.28

Market Cap

3.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CRNX
BGSI
Founded
2008
1990
Country
United States
Canada
Employees
N/A
13449
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.5B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
CRNX
BGSI
Price
$36.70
$97.28
Analyst Decision
Strong Buy
Buy
Analyst Count
8
1
Target Price
$76.75
$157.00
AVG Volume (30 Days)
1.0M
24.0K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
0.38%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$720.10
$35.07
Revenue Next Year
$184.67
$8.01
P/E Ratio
N/A
$231.07
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$88.97
52 Week High
$57.99
$183.10

Technical Indicators

Market Signals
Indicator
CRNX
BGSI
Relative Strength Index (RSI) 52.34 44.72
Support Level $33.14 $94.77
Resistance Level $44.89 $110.36
Average True Range (ATR) 1.63 3.44
MACD 0.29 0.61
Stochastic Oscillator 68.55 56.25

Price Performance

Historical Comparison
CRNX
BGSI

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About BGSI Boyd Group Services Inc.

Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.

Share on Social Networks: